There was a mistake in Figure 3 as published. One image was wrongly used in Figure 3B (left middle one), which is the same as in Figure 3C (right middle one). The corrected Figure 3 appears below.
Figure 3.
The histological morphology and mitochondrial ultrastructure in the spinal cord and cerebellum of Irp2−/− mice are improved after PT-2385 administration. (A) The hematoxylin–eosin (H&E)-stained sections of the cerebellum of WT DMSO, Irp2−/− DMSO, and Irp2−/− PT-2385 mice. The dotted lines indicate Purkinje cell layers (top), and the arrows point to Purkinje cells (middle). The Purkinje cells framed by the dotted line are magnified four times (bottom). The scale bars are 160, 80, and 20 μm, respectively. (B, C) Transmission electron micrographs of the cerebellum (B) and spinal cord (C) of WT DMSO, Irp2−/− DMSO, and Irp2−/− PT-2385 mice. The scale bars are 1, 2.5, and 5 μm, respectively. The bottom panels are magnified images of myelin sheath and axonal degeneration. (D) The quantification of a normal mitochondria (relative ratio comparing with that in WT). Values represented the mean ± SD, n = 3. The ANOVA was used for statistics to evaluate the group differences. *P < 0.05, ****P < 0.0001, Irp2−/− DMSO vs. WT DMSO; #P < 0.05, ##P < 0.01, Irp2−/− PT-2385 vs. Irp2−/− DMSO.
The original version of this article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.